The agent is an improved form of widely used anti-cancer drug Paclitaxel and has been approved by drugs controller-general of India.
The company would start the clinical trials for the product in the US and Europe and expects to launch it there in another 18-36
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Discussion Group